Form 4: Regeneron Executive Jason Pitofsky Reports Stock Transactions and Option Grant

Regeneron's VP Controller, Jason Pitofsky, reports the acquisition of restricted stock and stock options, along with the disposal of shares to cover tax obligations.

Summary

• Jason Pitofsky, VP Controller at Regeneron Pharmaceuticals, reported several transactions involving the company's stock.
• On December 6, 2024, Pitofsky acquired 907 shares of common stock as a restricted stock award, which will vest in two equal installments on December 6, 2026 and December 6, 2028.
• Also on December 6, 2024, Pitofsky was granted a non-qualified stock option to purchase 3,236 shares of common stock at an exercise price of $771.64, vesting in four equal annual installments starting one year after the grant date.
• On December 9, 2024, 149 shares were disposed of to cover tax obligations related to the vesting of restricted stock.
• Additionally, there were acquisitions of common stock on April 4, 2024 and April 29, 2024, through a trust, and holdings through a 401(k) plan.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align executive interests with company performance. There are no negative surprises or concerns.

Positives

• The grant of restricted stock and stock options to a key executive like Jason Pitofsky aligns his interests with the long-term performance of the company.
• The vesting schedule of the restricted stock encourages long-term commitment from the executive.
• The stock option grant provides an incentive for the executive to contribute to the company's growth and increase shareholder value.

Negatives

• The disposal of 149 shares to cover tax obligations indicates a reduction in the executive's direct holdings, although this is a common practice.

Risks

• There are no specific risks mentioned in this document, as it primarily details stock transactions and option grants.
• However, any significant changes in the executive's holdings could potentially signal a shift in their confidence in the company's future performance.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This type of stock transaction is common for executives in publicly traded companies, aligning their interests with shareholders and incentivizing performance. The vesting schedules are standard practice to ensure long-term commitment.

Comparison to Industry Standards

• Stock option grants and restricted stock awards are standard compensation practices for executives in the pharmaceutical industry, similar to companies like Amgen, Gilead Sciences, and AbbVie.
• The vesting schedules for both the restricted stock and stock options are typical, with vesting periods ranging from 2 to 4 years.
• The disposal of shares to cover tax obligations is a common occurrence among executives receiving equity-based compensation.

Stakeholder Impact

• The stock transactions and option grants are likely to have a positive impact on shareholders as they incentivize executive performance.
• Employees may view these grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Regeneron, Stock Options, Restricted Stock, Insider Trading, Executive Compensation, Form 4, Jason Pitofsky